FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry, specifically to a heterocyclic compound of formula (I), wherein W1 is N or CRC; W2 and W3 are CRC; Z is CN or ; X is H, (C1-C6)alkyl, wherein (C1-C6)alkyl is optionally substituted with 1 substituent independently selected from ORa; Y is (C3-C6)cycloalkyl or (C6-C10)aryl, where each (C6-C10)aryl is substituted with 2 substituents selected from F; R1 is Cl or ORa; each Ra independently is H or (C1-C6)alkyl; and each Rc is independently H. Also, the invention relates to a pharmaceutical composition based on a compound of formula
.
EFFECT: technical result is obtaining novel heterocyclic compounds which modulate the activity of tyrosine kinase, which is phosphatidylinositol 3-kinase (PI3K) and MPM (mTOR) and are useful in the treatment of proliferative diseases.
8 cl, 8 tbl, 15 ex
Title | Year | Author | Number |
---|---|---|---|
HETEROAROMATIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE MODULATORS AND METHODS OF USE | 2013 |
|
RU2665036C9 |
SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | 2013 |
|
RU2650895C2 |
N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2010 |
|
RU2607635C2 |
AZALACTAM COMPOUNDS AS INHIBITORS OF HPK1 | 2021 |
|
RU2819642C1 |
INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGUES AND USE THEREOF AS THERAPEUTIC AGENTS AND DIAGNOSTIC SAMPLES | 2009 |
|
RU2537945C2 |
TRAF 6 INHIBITORS | 2017 |
|
RU2770404C2 |
ARYL- AND HETEROARYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES OF UREA, METHOD FOR INHIBITION OF RAF KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITION | 1998 |
|
RU2265597C2 |
COMPOUNDS AND COMPOSITIONS AS ITPKb INHIBITORS | 2007 |
|
RU2425826C2 |
CONDENSED HETEROARYLS AND THEIR APPLICATION | 2011 |
|
RU2552114C2 |
Authors
Dates
2018-11-21—Published
2014-02-15—Filed